Kenta Takashima
YOU?
Author Swipe
View article: Successful Bronchial Occlusion With an Endobronchial Watanabe Spigot Using a Single‐Use Bronchoscope for Bronchobiliary Fistula: A Case Report
Successful Bronchial Occlusion With an Endobronchial Watanabe Spigot Using a Single‐Use Bronchoscope for Bronchobiliary Fistula: A Case Report Open
Bronchobiliary fistula (BBF) is a rare condition characterised by a pathological communication between the biliary tract and bronchial tree secondary to various diseases. Treatment includes bronchial occlusion using reusable bronchoscopes,…
View article: A Case of Stevens–Johnson Syndrome Triggered by Methicillin‐Resistant <i>Staphylococcus aureus</i> Infection During Pembrolizumab Treatment for Lung Squamous Cell Carcinoma
A Case of Stevens–Johnson Syndrome Triggered by Methicillin‐Resistant <i>Staphylococcus aureus</i> Infection During Pembrolizumab Treatment for Lung Squamous Cell Carcinoma Open
Pembrolizumab can cause extremely serious skin disorders with high mortality rates, such as Stevens–Johnson syndrome (SJS), with most cases occurring early after immune checkpoint inhibitor treatment. This report describes a patient that d…
View article: Extended 73‐month survival in an elderly patient with <scp>BRAF V600E</scp>‐mutated lung adenocarcinoma: A case report
Extended 73‐month survival in an elderly patient with <span>BRAF V600E</span>‐mutated lung adenocarcinoma: A case report Open
BRAF is a mediator that activates the mitogen‐activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dab…
View article: Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study Open
The patients who were T790M-positive in the first-line treatment with first or second-generation EGFR-TKIs and were given osimertinib as the second or later line treatment had a better prognosis than the patients who were T790M-negative in…
View article: Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan’s public healthcare system
Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan’s public healthcare system Open
Driven by lower retreatment and AE rates, WAVE was a cost-effective and cost-saving treatment for moderate-to-severe BPH in Japan compared to PUL, providing better outcomes at lower costs to the healthcare system.